PBKR03 / Passage Bio - LARVOL DELTA

GALax-C: Study of Safety, Tolerability and Efficacy of PBKR03 in Pediatric Subjects With Early Infantile Krabbe Disease (clinicaltrials.gov) - P1/2 | N=24 | Suspended | Sponsor: Passage Bio, Inc. | Active, not recruiting ➔ Suspended

Trial suspension • Pediatrics

GALax-C: Study of Safety, Tolerability and Efficacy of PBKR03 in Pediatric Subjects With Early Infantile Krabbe Disease (clinicaltrials.gov) - P1/2 | N=24 | Active, not recruiting | Sponsor: Passage Bio, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Pediatrics • NEFL

GALax-C: Study of Safety, Tolerability and Efficacy of PBKR03 in Pediatric Subjects With Early Infantile Krabbe Disease (clinicaltrials.gov) - P1/2; N=24; Recruiting; Sponsor: Passage Bio, Inc.; Initiation date: Sep 2021 ➔ Feb 2022

Trial initiation date • Pediatrics • MRI

GALax-C: Study of Safety, Tolerability and Efficacy of PBKR03 in Pediatric Subjects With Early Infantile Krabbe Disease (clinicaltrials.gov) - P1/2; N=24; Recruiting; Sponsor: Passage Bio, Inc.; Not yet recruiting ➔ Recruiting; Initiation date: Jun 2021 ➔ Sep 2021

Clinical • Enrollment open • Trial initiation date • Pediatrics • MRI

GALax-C: Study of Safety, Tolerability and Efficacy of PBKR03 in Pediatric Subjects With Early Infantile Krabbe Disease (clinicaltrials.gov) - P1/2; N=24; Not yet recruiting; Sponsor: Passage Bio, Inc.

Clinical • New P1/2 trial • Pediatrics • MRI

Study to assess safety, tolerability and efficacy of PBKR03 in pediatric subjects with Krabbe disease (GALax-C) (clinicaltrialsregister.eu) - P1/2; N=28; Sponsor: Passage Bio, Inc.

Clinical • New P1/2 trial • Lysosomal Storage Diseases • Metabolic Disorders • Pediatrics • Rare Diseases • MRI • Plasma NfL